Moderna has sought to bring to market an influenza vaccine built on the same messenger RNA technology that underpinned the Covid-19 vaccines developed during the pandemic. Whether U.S. regulators have granted approval for the shot, and on what date, could not be independently confirmed for this report and would need to be verified through the Food and Drug Administration directly.

The effort marks a possible new chapter for a technology that moved from the laboratory to widespread public use only a few years ago. Traditional flu vaccines rely on growing influenza virus in eggs or cells, a process that takes months. mRNA vaccines instead deliver genetic instructions that prompt the body's own cells to produce a protein that trains the immune system. Because that approach can be adjusted more quickly, it has drawn interest as a way to keep pace with the influenza strains that circulate and change from season to season.

For Moderna, the pursuit follows a lengthy regulatory process. The company has worked to broaden its portfolio beyond Covid-19 products, and a flu shot would represent one of its first steps into a new mRNA product outside of that arena.

Seasonal influenza causes a substantial burden of illness in the United States each year. Federal health estimates place the toll at hundreds of thousands of hospitalizations and tens of thousands of deaths in a typical season, with the figures varying widely from year to year. Existing flu vaccines are widely available and recommended for most Americans, and an mRNA option would add another tool to that effort.

Any approval would clear the way for the vaccine to be marketed, though its availability, pricing, and the specific recommendations for who should receive it would take shape through the steps that follow, including guidance from public health advisers on how the shot fits into seasonal vaccination.

mRNA technology has been the subject of continued public debate since its rapid deployment against Covid-19. Supporters point to the speed with which mRNA vaccines can be designed and updated as a significant advantage, particularly for a virus like influenza that shifts each year. The technology has also faced scrutiny and skepticism from some quarters.

Attention now centers on how such a vaccine would be produced, distributed, and taken up by the public, and whether an mRNA approach can match or improve upon the protection offered by the flu vaccines already in use.

References

1. 1.U.S. Food and Drug Administration — required to confirm the existence, date, and terms of any approval of Moderna's mRNA flu vaccine
2. 2.Moderna Inc. — company statements on its influenza vaccine development and regulatory filings
3. 3.U.S. Centers for Disease Control and Prevention — estimates of seasonal influenza hospitalizations and deaths, and vaccine recommendations
4. 4.Advisory Committee on Immunization Practices — guidance on how any new flu vaccine would fit into seasonal vaccination recommendations